Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 27, 2026

FlightPath Golf Tees Get Reviewed for Effective Accuracy and Distance - Results Inside

View original at globenewswire.com
FlightPath Golf Tees Get Reviewed for Effective Accuracy and Distance - Results Inside Altamonte Springs, FL, March 26, 2026 (GLOBE NEWSWIRE) -- FlightPath Golf conducts ongoing product evaluation and performance analysis as part of its development process…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • No swing changes are required to use FlightPath tees; the setup process is slightly different but becomes natural after a short adjustment period

    60% confidence

  • Each FlightPath tee is designed to last over 100 rounds due to impact-resistant polycarbonate construction

    60% confidence

  • The angled launch platform design reduces backspin on drives, which may translate to more carry distance without requiring swing modifications

    60% confidence

  • FlightPath tees are manufactured in Cocoa Beach, Florida and are 100% made and patented in the USA

    60% confidence

  • FlightPath tees have been reviewed by the USGA and issued an official conformance letter, making them legal for tournament use under USGA and R&A rules

    60% confidence

  • The diamond-patterned contact surface reduces friction in the direction of the swing, which may promote more consistent ball flight

    60% confidence

  • Traditional wooden tees break approximately every three holes according to Golf Magazine survey

    60% confidence

  • Third-party robotic testing demonstrated measurable differences in distance and precision

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com